Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Polypeptide > Abaloparatide for Sale > Abaloparatide peptide API
Abaloparatide peptide API buy - large image1
Abaloparatide peptide API buy - image1
Abaloparatide peptide API buy - image2
Abaloparatide peptide API buy - image3
Abaloparatide peptide API buy - image4
Abaloparatide peptide API buy - image5

Abaloparatide peptide API

46 Inquiries

Unit Price: Get Latest Price
CAS No.:

247062-33-5

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Hangzhou

Packaging:

50gram/bottle

Price valid (until):

2026-05-21

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

Semaglutide,Retatrutide,Tirzepatide,Linaclotide

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Product Usage

    Abaloparatide belongs to a class of medications known as parathyroid hormone-related protein (PTHrP) analogs. It is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), specifically its N-terminal fragment (1-34). Abaloparatide selectively binds to the parathyroid hormone type 1 receptor (PTH1R), activating the signaling pathway that stimulates bone formation.

    Abaloparatide is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It works by increasing bone mineral density (BMD) and reducing the risk of vertebral and non-vertebral fractures. Unlike anti-resorptive therapies that slow bone loss, abaloparatide is an anabolic agent that stimulates new bone formation.

    Clinical studies have demonstrated that abaloparatide significantly increases bone mineral density at the lumbar spine, femoral neck, and total hip. In the ACTIVE clinical trial, abaloparatide reduced the risk of new vertebral fractures by 86% and non-vertebral fractures by 43% compared to placebo over 18 months.

    Key Benefits:

    • Increases bone formation and mineral density

    • Reduces vertebral and non-vertebral fracture risk

    • Once-daily administration

    • Well-established safety profile for up to 2 years of treatment

    How much improvement can you expect with abaloparatide?

    Clinical trials have shown that patients taking abaloparatide experienced an average increase in lumbar spine bone mineral density of approximately 11% over 18 months, significantly reducing fracture risk.


    FAQ

    1. May I get a sample before placing an order?

    Yes, samples are available. For regular products, samples are free of charge and you only need to bear the freight. For high-value products, you need to pay for the freight and a certain product cost. When we cooperate for some time or when you become our VIP customer, free samples will be offered when needed.

    2. Which payment methods are available for your company?

    T/T, PayPal, bank transfer, and other options. You can choose the one that is most convenient for you.

    3. How and when can I get my goods after payment?

    For small quantities, products will be delivered by international courier (DHL, FedEx, TNT, etc.) or by air. Usually, it takes 5-7 days to receive the goods after shipment. For large quantities, shipping by sea is more cost-effective. It takes 15-30 days to reach your destination port, depending on the port location.

    4. Is it possible to use my own label or packaging?

    Yes. If needed, we can accommodate custom labeling and packaging requirements. Please provide your specifications and we will confirm feasibility.

    5. What is the purity and quality standard of your Abaloparatide API?

    Our Abaloparatide API is manufactured under cGMP standards with purity ≥99% by HPLC. We provide comprehensive documentation including COA, stability data, and DMF filing support.

    6. What is the recommended storage condition?

    Store at -20°C ± 5°C, dry, protected from light. The shelf life is 24 months under recommended storage conditions.

    7. Do you provide regulatory support for filing?

    Yes, we provide regulatory support including DMF filing assistance, documentation packages, and technical support for customer submissions.

    Company Profile

    Hangzhou ThinHeal Pharma-Tech Co., Ltd. (ThinHeal) is a high-tech enterprise specializing in the research, development, production, and sales of peptide products. The core management team is composed of professionals with a pharmaceutical background and nearly 20 years of management experience, positioning the company at the forefront of the industry.

    The company has a complete and efficient peptide R&D, production, and sales system, and provides a full range of peptide industrialization services, including:

    • Peptide API R&D and production business

    • Peptide customized R&D and production (CDMO) business

    • Beauty peptide research, development, and production business

    The company's revenue is mainly derived from peptide API sales and CDMO services. The company has successfully completed US FDA DMF filings for multiple products. The CDMO business includes project-based entrusted research and development, entrusted production, and sales. The main customers of the CDMO business are innovative drug companies and scientific research institutions, among which some pharmaceutical companies have cooperated with ThinHeal since the product development stage and have established solid cooperative relationships.

    ThinHeal is committed to providing high-quality peptide APIs and comprehensive technical support to customers worldwide, with a focus on regulatory compliance, supply chain reliability, and customer satisfaction.





    Shop Abaloparatide peptide API-Detailed Image 1
    Shop Abaloparatide peptide API-Detailed Image 2
    Shop Abaloparatide peptide API-Detailed Image 3

    Basic Info
    Product Name:

    Abaloparatide

    Other Name:

    Abaloparatide;Abaloparatide (BA058)

    CAS No.:

    247062-33-5

    Molecular Formula:

    C174H300N56O49

    InChIKeys:

    BVISQZFBLRSESR-XSCWXTNMSA-N

    Molecular Weight:

    3960.5896

    EC Number:

    218-362-5

    Color/Form:

    White to off-white

    Categories:

    Polypeptide

    Characteristics
  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Semaglutide,Retatrutide,Tirzepatide,Linaclotide

    Location:

    8th Floor, Building 2, Phase 5, Xiasha Heda Pharmaceutical Valley, Qiantang District, Hangzhou, Zhejiang Province

    Payment Terms:

    TT against copy of documents

    Average lead Time:

    7

    Total Annual Revenue:

    $25 million-$50 million

    Total Employees:

    301-500

    Year of Establishment:

    2019

    Certifications:

    WC,GMP

    杭州信海医药科技有限公司成立于2019年,是一家专注于多肽产品的研发、生产、销售与定制、研发生产相结合的生物医药企业。核心管理团

    队由具有深厚医药专业背景的专业人士组成。信海医药建有一个研发中心和两个生产基地,目前化学合成多肽总产能已达数吨级规模。


         公司具备完整高效的多肽研发、生产及销售体系,提供全方位的多肽产业化服务,包括原料药研发和生产业务、制剂研发业务、多肽定制研发生产(CDMO)业务、以及美容肽研发生产业务。现阶段产品主要包括司美格鲁肽、替尔泊肽、利那洛肽、瑞塔鲁肽等数十个品种,其中司美格鲁肽、替尔泊肽、利那洛肽等多个品种已完成美国FDA DMF备案。

         公司以固、液相结合的化学合成工艺手段为驱动,建有复杂多肽及类肽化学合成及修饰平台、多肽片段设计与合成技术平台、多分离手段纯化平台等完善研发体系,拥有一支130人以上研发队伍,博士、硕士学历人员占比近20%,核心研发团队拥有超过20年的多肽药物开发经验,具备深厚的专业背景和丰富的实践经验.

  • Inquiry History
    46 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Abaloparatide – Sequence length: 34 amino acids

    10 MG Aug 15, 2025
    United Kingdom

    Abaloparatide

    10 G Dec 18, 2025
    Australia

    Abaloparatide

    25 MG Jun 28, 2026
    United States

    abaloparatide-cas247062

    100 MG Jun 3, 2026
    United States

    Abaloparatide

    Jun 3, 2026
    United States

    abaloparatide

    1 G May 23, 2026
    United States

    Abaloparatide

    100 MG May 20, 2026
    United States

    Abaloparatide

    1 G Mar 24, 2026
    United States

    Abaloparatide

    30 G Mar 19, 2026
    United Kingdom

    Abaloparatide

    1 G Mar 18, 2026
    United States

    usa warehouse Abaloparatide 99% white powder

    10 MG Feb 5, 2026
    Australia

    abaloparatide

    250 MG Sep 25, 2025
    United States

    Abaloparatide

    1 MT Sep 11, 2025
    United States

    Abaloparatide

    10 G Jun 20, 2025
    United States

    abaloparatide

    20 MG Jun 30, 2026
    United States

    Abaloparatide

    100 MG Jun 21, 2026
    Canada

    Abaloparatide

    16 G Jun 14, 2026
    Czech

    abaloparatide

    1000 MG Jun 12, 2026
    Netherlands

    Abaloparatide

    50 MG Jun 5, 2026
    Australia

    Ablopartide

    10 MG May 24, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.